Helix Biopharma Corp.
3-305 Industrial Parkway
Aurora
Ontario
L4G 6X7
Canada
Tel: 905-841-2300-Ext-232
Fax: 905-841-2244
Website: http://www.helixbiopharma.com/
291 articles about Helix Biopharma Corp.
-
Helix Biopharma Corp. Closes Private Placement - Apr 21, 2022
4/21/2022
Helix BioPharma Corp. announces that it has closed a private placement financing for net proceeds of $2,002,000 from the issuance of 7,700,000 common shares at a price of $0.26 per common share.
-
Helix Biopharma Corp. Announces Appointment of Permanent CEO and Independent Board Members
4/18/2022
Helix BioPharma Corp. is pleased to announce that Artur Gabor has been appointed as the Company's Chief Executive Officer with immediate effect.
-
Helix Biopharma Corp. Announces Extension of Early Warrant Exercise Incentive Program and Receipt of Private Placement Subscription
4/13/2022
Helix BioPharma Corp. is pleased to announce that it has received conditional approval from the Toronto Stock Exchange to extend its previously announced Early Warrant Exercise Incentive Program from April 28, 2022 to May 31, 2022.
-
Helix Announces Board Resignation
4/7/2022
Helix BioPharma Corp., a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, announced the resignation of Dr. Krzysztof Saczek from the Board of Directors with immediate effect.
-
Helix Biopharma Corp. Announces Fiscal 2022 Second Quarter Results
3/16/2022
Helix BioPharma Corp., a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, announced fiscal 2022 second quarter results for the period ending January 31, 2022.
-
Helix Biopharma Corp. Announces Unexpected Passing of Interim CEO and Chairman of the Board
3/16/2022
Helix BioPharma Corp. today announces, with great sadness, the sudden passing of its Interim Chief Executive Officer and Chairman of the Board of Directors, Prof. Dr. S Slawomir Majewski.
-
CORRECTION: Helix Biopharma Corp. Closes Private Placement and Announces Early Warrant Exercise Incentive Program and Extension of Warrant Exercise Period
3/11/2022
Helix BioPharma Corp. announces that it has closed a private placement financing for gross proceeds of $1,001,000 from the issuance of 3,850,000 common share at a price of $0.26 per common share.
-
Helix Biopharma Corp. Closes Private Placement and Announces Early Warrant Exercise Incentive Program and Extension of Warrant Exercise Period
3/11/2022
Helix BioPharma Corp. announces that it has closed a private placement financing for gross proceeds of $1,001,000 from the issuance of 3,850,000 common share at a price of $0.26 per common share.
-
Helix BioPharma Corp. Reports Voting Results and Appointment of New Board Director
1/28/2022
Helix BioPharma Corp. today announced the voting results of the Company's annual and special meeting of shareholders held on January 28, 2022.
-
Helix BioPharma Corp. Provides Corporate Update - Dec 31, 2021
12/31/2021
Helix BioPharma Corp., an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to provide a corporate update on initiatives that were undertaken by the Company in 2021.
-
Helix Biopharma Corp. Announces Fiscal 2022 First Quarter Results
12/15/2021
Helix BioPharma Corp., a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, announced fiscal 2022 first quarter results for the period ending October 31, 2021.
-
Helix Biopharma Corp. Announces Fiscal 2021 Year-End Results
12/9/2021
Helix BioPharma Corp., a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, announced financial results for the 2021 fiscal year ended July 31, 2021.
-
Helix BioPharma Corp. Provides Third Bi-Weekly MCTO Status Update
11/30/2021
Helix BioPharma Corp. is providing this bi-weekly update on the status of the management cease trade order granted on November 1, 2021.
-
Helix BioPharma Corp. Provides Second Bi-Weekly MCTO Status Update
11/15/2021
Helix BioPharma Corp. is providing this bi-weekly update on the status of the management cease trade order granted on November 1, 2021 by its principal regulator, the Ontario Securities Commission under National Policy 12-203 Management Cease Trade Orders.
-
Helix BioPharma Corp. Announces Delay of Annual Filings
10/15/2021
Helix BioPharma Corp. announced that it anticipates the filing of its annual financial statements, management's discussion and analysis, annual information form and related officer certifications for the financial year ended July 31, 2021 will be delayed beyond the required filing deadline.
-
Helix BioPharma Corp. Announces Appointment of New Director
8/19/2021
Helix BioPharma Corp. today announced that Dr. Krzysztof Saczek has been appointed as a member of the Board of Directors of the Company effective immediately.
-
Helix BioPharma Corp. Announces Appointment of New Auditor and Extends Period to Exercise Warrants
6/24/2021
Helix BioPharma Corp., an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announced that it has appointed Marcum LLP as the Company's new auditor, replacing BDO Canada LLP.
-
Helix BioPharma Corp. Announces Fiscal Third Quarter 2021 Results
6/14/2021
Helix BioPharma Corp., a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, announced its financial results for the fiscal third quarter ended April 30, 2021.
-
Helix BioPharma Corp. Announces Closing of First Tranche of Institutional Investment for Gross Proceeds of CAD$3.5 million
5/13/2021
Helix BioPharma Corp. announced that it has closed the first tranche of the previously announced private placement pursuant to the convertible security funding agreement with Lind Global Macro Fund, LP, a New York based institutional investment fund managed by The Lind Partners, LLC for gross proceeds of CAD$3.5 million.
-
Helix BioPharma Corp. Announces Institutional Investment for Gross Proceeds of up to CAD$10 million
5/11/2021
Helix BioPharma Corp. an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has entered into a definitive convertible security funding agreement with Lind Global Macro Fund, LP, a New York based institutional investment fund managed by The Lind Partners, LLC